NASDAQ:ASLN ASLAN Pharmaceuticals (ASLN) Stock Price, News & Analysis → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free ASLN Stock Alerts $0.47 +0.01 (+2.18%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$0.45▼$0.5250-Day Range$0.41▼$1.6352-Week Range$0.39▼$4.69Volume1.48 million shsAverage Volume1.00 million shsMarket Capitalization$7.67 millionP/E RatioN/ADividend YieldN/APrice Target$11.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ASLAN Pharmaceuticals alerts: Email Address ASLAN Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,316.5% Upside$11.33 Price TargetShort InterestHealthy0.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.07Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.68) to ($2.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.69 out of 5 stars 3.5 Analyst's Opinion Consensus RatingASLAN Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageASLAN Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.73% of the float of ASLAN Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverASLAN Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ASLAN Pharmaceuticals has recently decreased by 59.79%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldASLAN Pharmaceuticals does not currently pay a dividend.Dividend GrowthASLAN Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ASLN. Previous Next 2.3 News and Social Media Coverage News SentimentASLAN Pharmaceuticals has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for ASLAN Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for ASLN on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows21 people have added ASLAN Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ASLAN Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.69% of the stock of ASLAN Pharmaceuticals is held by insiders.Percentage Held by Institutions58.82% of the stock of ASLAN Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ASLAN Pharmaceuticals are expected to grow in the coming year, from ($2.68) to ($2.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ASLAN Pharmaceuticals is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ASLAN Pharmaceuticals is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About ASLAN Pharmaceuticals Stock (NASDAQ:ASLN)ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.Read More ASLN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASLN Stock News HeadlinesApril 22, 2024 | markets.businessinsider.comAslan Announces Positive Results For Phase 2 Study Of Eblasakimab In AD PatientsApril 22, 2024 | globenewswire.comASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis PatientsApril 23, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.April 20, 2024 | finanznachrichten.deASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Announces Receipt of Nasdaq NoticeApril 19, 2024 | globenewswire.comASLAN Pharmaceuticals Announces Receipt of Nasdaq NoticeApril 16, 2024 | americanbankingnews.comASLAN Pharmaceuticals' (ASLN) Buy Rating Reaffirmed at HC WainwrightApril 14, 2024 | finanznachrichten.deASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateApril 12, 2024 | msn.comASLAN Falls On Q4 FiguresApril 23, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.April 12, 2024 | markets.businessinsider.comASLN Stock Earnings: ASLAN Pharma Misses EPS for Q4 2023April 12, 2024 | globenewswire.comASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 27, 2024 | globenewswire.comAslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and DisordersMarch 18, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Urogen Pharma (URGN) and Legend Biotech (LEGN)March 18, 2024 | finance.yahoo.comASLN Apr 2024 5.000 callMarch 17, 2024 | seekingalpha.comWeek In Review: Under Pressure From U.S. Congress, WuXi AppTec Resigns From BIOMarch 14, 2024 | finance.yahoo.comSmart Home Healthcare Market to Reach USD 160.7 Billion by 2032, at 24.3% CAGR: Astute AnalyticaMarch 14, 2024 | finance.yahoo.comREGN May 2024 885.000 callMarch 12, 2024 | msn.comASLAN Pharmaceuticals announces $5M registered direct offeringMarch 12, 2024 | globenewswire.comASLAN Pharmaceuticals Announces $5 Million Registered Direct OfferingMarch 12, 2024 | realmoney.thestreet.comPiper 'confident' partner or buyer will see benefit of Aslan's eblasakimabMarch 11, 2024 | msn.comU.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.12%March 11, 2024 | msn.comBank Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Monday TradingMarch 6, 2024 | finance.yahoo.comASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific AdvisorsMarch 4, 2024 | msn.comAsian Equities Traded in US as ADRs Edge Higher Monday AfternoonFebruary 29, 2024 | msn.comTech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Thursday TradingFebruary 29, 2024 | globenewswire.comASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for FarudodstatFebruary 28, 2024 | msn.comBank, Auto Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower WednesdaySee More Headlines Receive ASLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ASLAN Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/12/2024Today4/23/2024Next Earnings (Estimated)4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ASLN CUSIPN/A CIK1722926 Webwww.aslanpharma.com Phone65-6817-9598Fax65-6225-2419Employees35Year FoundedN/APrice Target and Rating Average Stock Price Target$11.33 High Stock Price Target$15.00 Low Stock Price Target$9.00 Potential Upside/Downside+2,316.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-44,220,000.00 Net MarginsN/A Pretax Margin-367.39% Return on Equity-8,454.87% Return on Assets-95.72% Debt Debt-to-Equity RatioN/A Current Ratio1.84 Quick Ratio1.84 Sales & Book Value Annual Sales$12 million Price / Sales0.64 Cash FlowN/A Price / Cash FlowN/A Book Value($0.81) per share Price / Book-0.58Miscellaneous Outstanding Shares16,350,000Free Float15,583,000Market Cap$7.67 million OptionableOptionable Beta1.45 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Carl Alan Jason Morton Firth EMBA (Age 51)Ph.D., Founder, CEO & Executive Director Mr. Kiran Kumar Asarpota (Age 45)COO & Head of Finance Mr. Ben Goodger (Age 61)General Counsel Mr. Stephen Doyle (Age 51)Chief Business Officer Dr. Alexandre Kaoukhov M.D. (Age 50)Chief Medical Officer Charlie HsuInvestor Relations DirectorChi-Chin WangIR & Corporate Development DirectorMore ExecutivesKey CompetitorsClever LeavesNASDAQ:CLVRObsEvaNASDAQ:OBSVLixte BiotechnologyNASDAQ:LIXTPulmatrixNASDAQ:PULMTFF PharmaceuticalsNASDAQ:TFFPView All Competitors ASLN Stock Analysis - Frequently Asked Questions Should I buy or sell ASLAN Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ASLAN Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ASLN shares. View ASLN analyst ratings or view top-rated stocks. What is ASLAN Pharmaceuticals' stock price target for 2024? 3 analysts have issued twelve-month price objectives for ASLAN Pharmaceuticals' stock. Their ASLN share price targets range from $9.00 to $15.00. On average, they predict the company's stock price to reach $11.33 in the next year. This suggests a possible upside of 2,316.5% from the stock's current price. View analysts price targets for ASLN or view top-rated stocks among Wall Street analysts. How have ASLN shares performed in 2024? ASLAN Pharmaceuticals' stock was trading at $0.5221 at the beginning of 2024. Since then, ASLN shares have decreased by 10.2% and is now trading at $0.4690. View the best growth stocks for 2024 here. Are investors shorting ASLAN Pharmaceuticals? ASLAN Pharmaceuticals saw a decrease in short interest in March. As of March 31st, there was short interest totaling 116,800 shares, a decrease of 59.8% from the March 15th total of 290,500 shares. Based on an average trading volume of 979,300 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.7% of the shares of the stock are sold short. View ASLAN Pharmaceuticals' Short Interest. When is ASLAN Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024. View our ASLN earnings forecast. How were ASLAN Pharmaceuticals' earnings last quarter? ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) announced its earnings results on Friday, April, 12th. The company reported ($0.78) EPS for the quarter. When did ASLAN Pharmaceuticals' stock split? ASLAN Pharmaceuticals shares reverse split on the morning of Monday, March 13th 2023. The 1-5 reverse split was announced on Monday, March 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of ASLAN Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ASLAN Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Onconova Therapeutics (ONTX), Aldeyra Therapeutics (ALDX), SCYNEXIS (SCYX) and VBI Vaccines (VBIV). When did ASLAN Pharmaceuticals IPO? ASLAN Pharmaceuticals (ASLN) raised $60 million in an initial public offering on Friday, May 4th 2018. The company issued 7,500,000 shares at $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers. How do I buy shares of ASLAN Pharmaceuticals? Shares of ASLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ASLN) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ASLAN Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
